Logo

Vanderbilt Researchers to Use FGT s Data Management System to Study Genetics of Drug Side Effects

Jan 18, 2005

NEW YORK, Jan. 18 (GenomeWeb News) - First Genetic Trust will provide the VanderbiltUniversityMedicalCenterwith its genetic data management system to further study the genetics of drug side effects, the two organizations said yesterday.

 

Vanderbilt researchers plans to use FGT's web-based EnTrust study-management system to expand their research on the genetics of drug-induced prolonged QT, a side effect for many different drug classes.

 

The system allows the VUMC researchers to enroll patients referred by other clinicians electronically. FGT's platform will be used to manage online informed consent, samples, clinical data, and genetic data. First Genetic Trust is headquartered in Chicago.

 

Financial terms of the agreement were not disclosed.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.